AI 检索
AI 阅读
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.

Overall survival (OS) with first-line atezolizumab (A) or placebo (P) in combination with vemurafenib (V) and cobimetinib (C) in BRAFV600 mutation-positive advanced melanoma: Second interim OS analysis of the phase 3 IMspire150 study.

Grant A. McArthur,Ralf Gutzmer,Daniil Stroyakovskiy,Helen Gogas,Caroline Robert,Svetlana Protsenko,Rodrigo Perez Pereira,Thomas Eigentler,Piotr Rutkowski,Lev V. Demidov,Natalia V. Zhukova,Jacob Schachter,Yibing Yan,Ivor Caro,Christian Hertig,Cloris Xue,Lieke Kusters,Paolo Antonio Ascierto,Karl D. Lewis

JOURNAL OF CLINICAL ONCOLOGY（2022）

引用 5|浏览6
暂无评分
关键词
melanoma,vemurafenib,second interim os analysis,first-line,mutation-positive
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要